Growing evidence supports abnormally activated mTOR to play an important pathogenic role in lung cancer associated with both KRAS and EGFR mutations and may provide a mechanism of resistance to treatment with EGFR inhibitors [26,27]. Here, EGFR is linked to lung cancer.